Edwards Lifesciences Corporation (NYSE:EW) VP Catherine M. Szyman sold 4,681 shares of Edwards Lifesciences Corporation stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $115.78, for a total value of $541,966.18. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Edwards Lifesciences Corporation (EW) traded down 0.41% on Friday, reaching $113.11. The company’s stock had a trading volume of 1,134,626 shares. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.75. The company’s 50 day moving average price is $116.42 and its 200-day moving average price is $106.02. The stock has a market cap of $23.88 billion, a PE ratio of 34.31 and a beta of 0.63.
Edwards Lifesciences Corporation (NYSE:EW) last posted its earnings results on Wednesday, July 26th. The medical research company reported $1.08 EPS for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.20. The business had revenue of $842 million during the quarter, compared to analyst estimates of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The company’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.76 EPS. On average, equities analysts expect that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Rincon Hill News and is the property of of Rincon Hill News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://rinconhillneighbors.org/2017/08/19/catherine-m-szyman-sells-4681-shares-of-edwards-lifesciences-corporation-ew-stock-updated-updated.html.
A number of analysts have recently commented on the company. Zacks Investment Research lowered Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, May 18th. BidaskClub lowered Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Bank of America Corporation lifted their price target on Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, July 27th. SunTrust Banks, Inc. raised their price objective on Edwards Lifesciences Corporation to $14.00 and gave the stock a “buy” rating in a research report on Monday, July 17th. Finally, Royal Bank Of Canada raised their price objective on Edwards Lifesciences Corporation from $116.00 to $120.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 26th. Five equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. Edwards Lifesciences Corporation presently has an average rating of “Buy” and a consensus price target of $121.13.
Hedge funds have recently bought and sold shares of the company. Quadrant Capital Group LLC raised its stake in Edwards Lifesciences Corporation by 3.5% in the first quarter. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company’s stock worth $109,000 after buying an additional 41 shares during the last quarter. YorkBridge Wealth Partners LLC acquired a new stake in Edwards Lifesciences Corporation during the first quarter worth approximately $110,000. ETF Managers Group LLC purchased a new position in Edwards Lifesciences Corporation during the second quarter worth about $112,000. NEXT Financial Group Inc increased its position in Edwards Lifesciences Corporation by 91.7% in the first quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock worth $115,000 after buying an additional 500 shares during the period. Finally, Shine Investment Advisory Services Inc. purchased a new position in Edwards Lifesciences Corporation during the second quarter worth about $126,000. 84.67% of the stock is owned by institutional investors and hedge funds.
Edwards Lifesciences Corporation Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with our FREE daily email newsletter.